Contact UsQuotation
Shopping Cart
Remove All
  • TargetMol
    Your shopping cart is currently empty
Proceed to checkoutContinue shopping
TOPBioactivityChemical infoStorage&SolubilityCalculator

Tirzepatide Acetate(2023788-19-2 free base)

Copy Product Info
🥰Excellent
Hot
Catalog No. TP1111L

Tirzepatide (LY3298176) Acetate (2023788-19-2 free base) is a new molecule that can control blood glucose levels by combining dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[3]

Tirzepatide Acetate(2023788-19-2 free base)
Other Forms of Tirzepatide Acetate(2023788-19-2 free base):

Tirzepatide Acetate(2023788-19-2 free base)

Copy Product Info
🥰Excellent
Hot
Purity: 98.05%
Catalog No. TP1111L
Tirzepatide (LY3298176) Acetate (2023788-19-2 free base) is a new molecule that can control blood glucose levels by combining dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[3]
Pack SizePriceUSA WarehouseGlobal WarehouseQuantity
1 mg$358In StockIn Stock
5 mg$798In StockIn Stock
10 mg$1,180In StockIn Stock
25 mg$1,680In StockIn Stock
Add to Cart
Add to Quotation
In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]
With extensive experience in compound synthesis, we can provide rapid custom synthesis services for this product according to your research needs.
All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.
Questions
TargetMol
View More

Batch Information

Select Batch
Purity:98.05%
Color:White
Contact us for more batch information

Resource Download

COA HPLC MS

Product Introduction

Bioactivity
Description
Tirzepatide (LY3298176) Acetate (2023788-19-2 free base) is a new molecule that can control blood glucose levels by combining dual agonism of glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors.[3]
Targets&IC50
GLP1 receptor:0.934 nM (EC50), GIPR:0.0224 nM (EC50)
In vitro
METHODS: Tirzepatide (LY3298176) (1, 3, 10, 30 nM) was used to treat GIPR or GLP-1R receptors, and Tirzepatide (30 μM, 30 nM) was used to treat cells expressing recombinant GIPR or GLP-1R to investigate whether it is effective on both GIPR and GLP-1R.
RESULTS In receptor binding studies, LY3298176 had high affinity to either receptor (GIPR Ki = 0.135, SEM = 0.020 nM; GLP-1R Ki = 4.23, SEM = 0.23 nM); for GIPR, the affinity was comparable to that of native GIP, while for GLP-1R, the affinity was approximately 5-fold weaker than that of native GLP-1. In signaling studies using the same HER2 receptors, LY3298176 potently stimulated cAMP accumulation at either receptor (GIPR EC50 = 0.0224, SEM = 0.0053 nM; GLP-1R EC50 = 0.934, SEM = 0.068 nM).[1]
METHODS: Representative confocal images of Tirzepatide (LY3298176)-induced receptor internalization and EGFP fluorescence in HA-GIPR-EGFP cells treated with Tirzepatide (LY3298176) (100 nM).
RESULTS Tirzepatide (LY3298176) was weak in inducing internalization, resulting in a maximal effect of only 40% of that observed with GLP-1. Treatment with Tirzepatide (LY3298176) resulted in minimal reduction in cell surface labeling and only a slight increase in punctate localization of the receptor in the cytoplasmic/perinuclear region. [2]
In vivo
METHODS: Tirzepatide (LY3298176) (30nmol/kg，i.p) was used to evaluate in vivo glycemic control using an intraperitoneal glucose tolerance test (ipGTT) in normal and receptor-deficient mice.
RESULTS Tirzepatide (LY3298176) enhanced insulin secretion in three pancreatic islet genotypes. Tirzepatide (LY3298176) can induce glucose-dependent insulin secretion in vivo through GIPR or GLP-1R and improve glucose tolerance in mice. [1]
Chemical Properties
Molecular Weight4873.5
FormulaC227H352N48O70
SmilesC[C@H]([C@@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NC(C)(C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(N[C@H](C(NCC(NCC(N1CCC[C@H]1C(N[C@H](C(N[C@H](C(NCC(N[C@H](C(N2CCC[C@H]2C(N3CCC[C@H]3C(N4CCC[C@H]4C(N[C@H](C(N)=O)CO)=O)=O)=O)=O)C)=O)=O)CO)=O)CO)=O)=O)=O)=O)C)=O)[C@H](CC)C)=O)CC(C)C)=O)CC5=CNC6=C5C=CC=C6)=O)CCC(N)=O)=O)C(C)C)=O)CC7=CC=CC=C7)=O)C)=O)CCCCNC(COCCOCCNC(COCCOCCNC(CC[C@H](C(O)=O)NC(CCCCCCCCCCCCCCCCCCC(O)=O)=O)=O)=O)=O)=O)CCC(N)=O)=O)C)=O)[C@H](CC)C)=O)CCCCN)=O)CC(O)=O)=O)CC(C)C)=O)C)=O)[C@H](CC)C)=O)CO)=O)CC8=CC=C(O)C=C8)=O)CC(O)=O)=O)CO)=O)[C@H](O)C)=O)CC9=CC=CC=C9)=O)NC(CNC([C@@H](NC(C(C)(NC([C@H](CC%10=CC=C(O)C=C%10)N)=O)C)=O)CCC(O)=O)=O)=O)O.CC(O)=O
Relative Density.no data available
Storage & Solubility Information
Storagekeep away from moisture | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.
Solubility Information
DMSO: 245 mg/mL (50.27 mM), Sonication is recommended.
H2O: < 1 mg/mL (insoluble or slightly soluble)
Solution Preparation Table
DMSO
1mg5mg10mg50mg
1 mM0.2052 mL1.0260 mL2.0519 mL10.2596 mL
5 mM0.0410 mL0.2052 mL0.4104 mL2.0519 mL
10 mM0.0205 mL0.1026 mL0.2052 mL1.0260 mL
20 mM0.0103 mL0.0513 mL0.1026 mL0.5130 mL
50 mM0.0041 mL0.0205 mL0.0410 mL0.2052 mL

Calculator

  • Molarity Calculator
  • Dilution Calculator
  • Reconstitution Calculator
  • Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:
TargetMol | Animal experiments For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent 10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH2O , the resulting working solution concentration would be 2 mg/mL.
Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSOTargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSOTargetMol | reagent stock solution to 400 μL PEG300TargetMol | reagent and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH2OTargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.
All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.
1 Enter information below:
mg/kg
g
μL
2 Enter the in vivo formulation:
% DMSO
%
% Tween 80
% Saline/PBS/ddH2O

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc

Keywords

Tirzepatide Acetate(2023788-19-2 free base)Tirzepatide Acetate(2023788192 free base)Tirzepatide Acetate(2023788 19 2 free base)GlucagonReceptorGlucagon Receptor
Related Tags: buy Tirzepatide Acetate(2023788-19-2 free base) | purchase Tirzepatide Acetate(2023788-19-2 free base) | Tirzepatide Acetate(2023788-19-2 free base) cost | order Tirzepatide Acetate(2023788-19-2 free base) | Tirzepatide Acetate(2023788-19-2 free base) chemical structure | Tirzepatide Acetate(2023788-19-2 free base) in vivo | Tirzepatide Acetate(2023788-19-2 free base) in vitro | Tirzepatide Acetate(2023788-19-2 free base) formula | Tirzepatide Acetate(2023788-19-2 free base) molecular weight
TargetMol | Logo

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.